HONG KONG, Sept. 15 /PRNewswire/ -- Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, and preclinical data from Combo Bio-engineered Sirolimus Eluting Stent will be presented next week at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2009, in San Francisco.
Robbert de Winter, M.D., Ph.D., of the Academic Medical Center in Amsterdam will provide the final 12-month outcomes from e-HEALING, a monitored, multi-center, worldwide (outside the United States) prospective registry with 5,000 enrolled patients. The oral presentation will take place at 1:16 p.m. PDT on Sept. 22 in room 104 at the Moscone Center.
In addition, de Winter and his colleagues will present a poster titled "Patients with diabetes mellitus in the worldwide e-HEALING registry have a low target lesion revascularization rate at 12-month follow-up." The poster can be reviewed from 8 a.m. PDT - 10 p.m. PDT on Sept. 22 in Hall D.
An additional poster titled "Routine use of an EPC-capturing stent in patients undergoing primary PCI for ST-segment elevation myocardial infarction: A prospective registry in all comers," will be presented by Jan-Henk Dambrink, M.D., Ph.D., of the Isala klieniken, Zwolle, Netherlands, and can be reviewed from 8 a.m. PDT - 10 p.m. PDT on Sept. 22 in Hall D.
Juan F Granada, M.D., medical director of the Skirball Center for Cardiovascular Research and assistant professor at Columbia University, New York, will present preclinical data of OrbusNeich's Combo Bio-engineered Sirolimus Eluting Stent, which is designed to combine the pro-healing technology used in OrbusNeich's Genous Bio-engineered R stent for rapid endothelial coverage and improved functionality with abluminal sirolimus sustained drug elution for the control of neointimal proliferation. The oral presentation titled "The OrbusNeich EPC-Coated Bioabsorbable Polymer Sirolimus-Eluting Stent Program" will take place at 2:31 p.m. PDT on Sept. 22 in room 104.
Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the placement of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.
OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005. The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.
OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent, Scoreflex(TM), SafeCut(TM), Sapphire(TM), Sapphire NC, Avita(TM), Avita HP and Lumina(TM). OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.
Editor's Notes: OrbusNeich will display the Genous Bio-engineered R stent and other products at booth No. 330 at TCT 2009. Product images are available on request.
Copyright©2009 PR Newswire.
All rights reserved